Search

Your search keyword '"Nout, Remi A"' showing total 243 results

Search Constraints

Start Over You searched for: Author "Nout, Remi A" Remove constraint Author: "Nout, Remi A" Database Unpaywall Remove constraint Database: Unpaywall
243 results on '"Nout, Remi A"'

Search Results

1. Prediction of recurrence risk in endometrial cancer with multimodal deep learning

2. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials

4. Survival of Women with Advanced Stage Cervical Cancer: Neo-Adjuvant Chemotherapy Followed by Radiotherapy and Hyperthermia versus Chemoradiotherapy

6. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation

7. HECTOR: multimodal deep learning predicts recurrence risk in endometrial cancer.

8. SO019LBA/#875 Molecular features predicts outcomes in multicentric international study of chemoradiation and MRI based image guided brachytherapy for cervical cancer (EMBRACE): final analysis from bioembrace-I

9. SO006/#55 Regular dilation and/or sexual activity show less risk for vaginal stenosis in cervical cancer patients

11. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, -2 and -3 trials

13. Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas

14. 127 Impact of Brachytherapy Applicator on Clinical Outcomes in Cervix Cancer: An EMBRACE-I Study Analysis

15. EviGUIDE - a tool for evidence-based decision making in image-guided adaptive brachytherapy for cervical cancer

17. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023

19. HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial

20. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer

21. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer

22. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*

23. ESTRO/ESGO/SIOPe guidelines for the management of patients with vaginal cancer

24. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*

25. Tools for large-scale data analytics of an international multi-center study in radiation oncology for cervical cancer

26. Abstract 5695: Deep learning risk prediction model of distant recurrence from H&E endometrial cancer slides

27. Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer

28. Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer

29. Supplementary Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer

30. Supplementary Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer

31. Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors

32. Supplementary figure 6 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

33. Supplementary Table S2 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

34. Table S3 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

35. Supplementary figure 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

36. Supplementary Table S5 from Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

37. Table S5 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

38. Figure S1 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

39. Supplementary figure 4 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

40. Figure S2 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

41. Supplementary table 2 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

42. Supplementary Figure S2 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

43. Figure S4 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma

44. Supplementary Figure S2 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

45. Figure S2 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma

46. Figure S7 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma

47. Figure S3 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

48. Table S1 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

49. Table S4 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

50. Table S2 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

Catalog

Books, media, physical & digital resources